Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PAT-1251 · 1 trial · 1 indication
Determination of adverse events will include assessment of vital signs, ECG, clinical laboratory and physical examination
| Arm | Type | Description |
|---|---|---|
| PAT-1251 Single Dose | EXPERIMENTAL | Oral solution of PAT-1251, 150 - 4000 mg administered once |
| Placebo Single Dose | PLACEBO_COMPARATOR | Matching placebo solution administered once |
| PAT-1251 Multiple Dose | EXPERIMENTAL | Oral tablet(s) of PAT-1251 up to 2000 mg administered daily for 7 days |
| Placebo Multiple Dose | EXPERIMENTAL | Matching placebo tablets administered daily for 7 days |
| Name | Type | Description |
|---|---|---|
| PAT-1251 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive * body weight of 50 to 100 kg, inclusive * subjects must be in good health Exclusion Criteria: * male subjects who do not agree, or whose partners of childbearing potential do not agree, to use appropriate contrace...
PAT-1251 is an investigational small molecule being studied for use in healthy adult subjects. It is currently in Phase 1 clinical development, with a completed trial evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers.
PAT-1251 is being developed by Damora Therapeutics, Inc., a biopharmaceutical company. The company's stock trades under the ticker symbol DMRA.
PAT-1251 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial has been completed, and the drug remains in early-stage clinical testing.
PAT-1251 has one completed clinical trial, NCT02852551, titled 'Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of PAT-1251 in Healthy Adult Subjects.' This Phase 1 study enrolled 78 participants in the United Kingdom.
Yes, PAT-1251 is being studied in healthy volunteers. The completed Phase 1 trial NCT02852551 enrolled healthy adult subjects aged 18 years and older, with a placebo-controlled, double-blind, randomized design.